Avalo Therapeutics (AVTX) EBT Margin (2016 - 2025)
Avalo Therapeutics (AVTX) posted EBT Margin of 23033.9% for Q4 2025, down 25.55% on a QoQ basis from 18346.35% in Q4 2024, and down 468754.0% year-over-year from N/an in Q4 2024.
Avalo Therapeutics (AVTX) EBT Margin (2016 - 2025) Analysis & Trends
Avalo Therapeutics' EBT Margin history runs 10 years deep, the most recent figure standing at 23033.9% for Q4 2025.
- Quarterly EBT Margin fell 468754.0% year-over-year to 23033.9% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 15618.8% (down 767889.0% YoY) and the FY2025 annual result came in at 132362.71%, down 12442280.0% from the prior year.
- EBT Margin was 23033.9% for Q4 2025 at Avalo Therapeutics, down from 18346.35% in the prior quarter.
- Across five years, EBT Margin topped out at 9246.18% in Q3 2024 and bottomed at 23033.9% in Q4 2025.
- A 5-year average of 4024.64% and a median of 1432.05% in 2023 frame the typical range for EBT Margin.
- Peak annual rise in EBT Margin reached 1145805 bps in 2024, while the deepest fall reached 1691431 bps in 2024.
- Avalo Therapeutics' EBT Margin stood at 8742.92% in 2021, then jumped by 87 bps to 1094.2% in 2022, then sank by 31 bps to 1432.05% in 2023, then tumbled by 1181 bps to 18346.35% in 2024, then slipped by 26 bps to 23033.9% in 2025.
- Business Quant data shows AVTX's EBT Margin at 23033.9% in Q4 2025, 18346.35% in Q4 2024, and 9246.18% in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17.13% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Avalo Therapeutics | 1.04 Mn | 1.04 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -23,033.90% |
| Dec 31, 2024 | -18,346.35% |
| Sep 30, 2024 | 9,246.18% |
| Dec 31, 2023 | -1,432.05% |
| Sep 30, 2023 | -2,211.86% |
| Jun 30, 2023 | -1,273.09% |
| Mar 31, 2023 | -2,094.11% |
| Dec 31, 2022 | -1,094.20% |
| Sep 30, 2022 | 21.39% |
| Jun 30, 2022 | -1,256.73% |
| Mar 31, 2022 | -1,879.11% |
| Dec 31, 2021 | -8,742.92% |
| Sep 30, 2021 | -1,293.56% |
| Jun 30, 2021 | -517.82% |
| Mar 31, 2021 | -6,461.52% |
| Dec 31, 2020 | -1,090.71% |
| Sep 30, 2020 | -1,193.34% |
| Jun 30, 2020 | -992.53% |
| Mar 31, 2020 | -882.79% |
| Dec 31, 2019 | -141.58% |